Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:ABCL NASDAQ:IMVT NASDAQ:KYMR NASDAQ:PCVX On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeABCLAbCellera Biologics$5.62-11.8%$4.42$2.38▼$6.79$1.95B1.188.83 million shs8.90 million shsIMVTImmunovant$31.11-4.8%$28.50$14.32▼$36.28$6.71B0.762.56 million shs864,698 shsKYMRKymera Therapeutics$74.13-0.6%$83.01$36.65▼$103.00$6.14B2.02494,538 shs639,437 shsPCVXVaxcyte$47.36-2.9%$55.20$29.08▼$65.00$7.04B1.241.47 million shs1.11 million shsA Guide To High-Short-Interest StocksMarketBeat's analysts have just released their top five short plays for June 2026. Learn which stocks have the most short interest and how to trade them. Click the link to see which companies made the list.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceABCLAbCellera Biologics-11.77%-8.91%+11.51%+62.90%+132.23%IMVTImmunovant-4.78%-6.58%+8.51%+16.69%+102.80%KYMRKymera Therapeutics-0.64%-8.95%-14.06%-11.21%+67.49%PCVXVaxcyte-2.87%-7.86%-17.06%-20.12%+39.95%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeABCLAbCellera Biologics$5.62-11.8%$4.42$2.38▼$6.79$1.95B1.188.83 million shs8.90 million shsIMVTImmunovant$31.11-4.8%$28.50$14.32▼$36.28$6.71B0.762.56 million shs864,698 shsKYMRKymera Therapeutics$74.13-0.6%$83.01$36.65▼$103.00$6.14B2.02494,538 shs639,437 shsPCVXVaxcyte$47.36-2.9%$55.20$29.08▼$65.00$7.04B1.241.47 million shs1.11 million shsA Guide To High-Short-Interest StocksMarketBeat's analysts have just released their top five short plays for June 2026. Learn which stocks have the most short interest and how to trade them. Click the link to see which companies made the list.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceABCLAbCellera Biologics-11.77%-8.91%+11.51%+62.90%+132.23%IMVTImmunovant-4.78%-6.58%+8.51%+16.69%+102.80%KYMRKymera Therapeutics-0.64%-8.95%-14.06%-11.21%+67.49%PCVXVaxcyte-2.87%-7.86%-17.06%-20.12%+39.95%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceABCLAbCellera Biologics 2.67Moderate Buy$7.8038.79% UpsideIMVTImmunovant 2.45Hold$37.3320.00% UpsideKYMRKymera Therapeutics 2.95Moderate Buy$118.1059.31% UpsidePCVXVaxcyte 2.63Moderate Buy$86.0081.59% UpsideCurrent Analyst Ratings BreakdownLatest ABCL, PCVX, IMVT, and KYMR Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails5/26/2026IMVTImmunovant GuggenheimSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetBuy$44.00 ➝ $62.005/22/2026IMVTImmunovant Truist FinancialSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetHold$23.00 ➝ $30.005/21/2026IMVTImmunovant CitigroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy5/21/2026IMVTImmunovant HC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetBuy$35.00 ➝ $40.005/21/2026IMVTImmunovant Bank of AmericaSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetBuy$32.00 ➝ $43.005/6/2026KYMRKymera Therapeutics Canaccord Genuity GroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageBuy$106.005/5/2026ABCLAbCellera Biologics Cantor FitzgeraldSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageOverweight$7.004/30/2026KYMRKymera Therapeutics Morgan StanleySubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingOverweight$119.004/21/2026KYMRKymera Therapeutics Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)4/20/2026ABCLAbCellera Biologics Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)4/15/2026IMVTImmunovant The Goldman Sachs GroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetNeutral$29.00 ➝ $32.00(Data available from 6/6/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookABCLAbCellera Biologics$75.13M22.84N/AN/A$3.23 per share1.74IMVTImmunovantN/AN/AN/AN/A$4.19 per shareN/AKYMRKymera Therapeutics$39.21M155.52N/AN/A$19.42 per share3.82PCVXVaxcyteN/AN/AN/AN/A$20.51 per shareN/ACompare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateABCLAbCellera Biologics-$146.41M-$0.48N/AN/AN/A-181.75%-14.86%-10.62%8/6/2026 (Estimated)IMVTImmunovant-$505.61M-$2.78N/AN/AN/AN/A-65.66%-59.88%8/10/2026 (Estimated)KYMRKymera Therapeutics-$311.35M-$3.57N/AN/AN/A-611.94%-24.71%-22.05%8/10/2026 (Estimated)PCVXVaxcyte-$766.63M-$6.88N/AN/AN/AN/A-32.51%-29.51%8/5/2026 (Estimated)Latest ABCL, PCVX, IMVT, and KYMR EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/20/2026Q4 2026IMVTImmunovant-$0.60-$0.73-$0.13-$0.73N/AN/A5/11/2026Q1 2026ABCLAbCellera Biologics-$0.22-$0.14+$0.08-$0.14$5.41 million$8.32 million5/6/2026Q1 2026PCVXVaxcyte-$1.7411-$2.30-$0.5589-$2.30$12.50 millionN/A4/30/2026Q1 2026KYMRKymera Therapeutics-$0.89-$0.71+$0.18-$0.71$8.27 million$34.37 millionCompare DividendsCompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive GrowthABCLAbCellera BiologicsN/AN/AN/AN/AN/AIMVTImmunovantN/AN/AN/AN/AN/AKYMRKymera TherapeuticsN/AN/AN/AN/AN/APCVXVaxcyteN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioABCLAbCellera BiologicsN/A14.0514.05IMVTImmunovantN/A9.099.09KYMRKymera TherapeuticsN/A10.8110.81PCVXVaxcyteN/A7.497.49Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipABCLAbCellera Biologics61.42%IMVTImmunovant47.08%KYMRKymera TherapeuticsN/APCVXVaxcyte96.78%Insider OwnershipCompanyInsider OwnershipABCLAbCellera Biologics28.40%IMVTImmunovant1.80%KYMRKymera Therapeutics15.98%PCVXVaxcyte3.30%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableABCLAbCellera Biologics500305.38 million218.65 millionOptionableIMVTImmunovant120205.31 million201.61 millionOptionableKYMRKymera Therapeutics17082.26 million69.11 millionOptionablePCVXVaxcyte160144.40 million139.63 millionOptionableABCL, PCVX, IMVT, and KYMR HeadlinesRecent News About These CompaniesWestfield Capital Management Co. LP Lowers Position in Vaxcyte, Inc. $PCVXJune 5 at 7:21 AM | marketbeat.comVaxcyte (NASDAQ:PCVX) COO Jim Wassil Sells 2,250 SharesJune 4 at 8:18 AM | insidertrades.comVaxcyte Doses First Participant in Phase 1 Study Evaluating VAX-A1 for the Prevention of Disease Caused by Group A Streptococcus in Healthy AdultsJune 2, 2026 | globenewswire.comWhy Vaxcyte (PCVX) Is Up 8.7% After Completing Key VAX-31 Phase 3 Trial EnrollmentsJune 1, 2026 | finance.yahoo.comVaxcyte (PCVX) Completes Enrollment for Phase 3 VAX-31 Clinical TrialsMay 30, 2026 | finance.yahoo.comVaxcyte Inc Ordinary Shares PCVXMay 28, 2026 | morningstar.comMVaccine Stocks Fall After FDA Plans to Impose Stricter Vaccine RulesMay 28, 2026 | msn.comVaxcyte (PCVX) slips 3.8% as investors digest recent ownership filings and cash-burn outlookMay 20, 2026 | quiverquant.comQAnalysts Offer Insights on Healthcare Companies: Vaxcyte (PCVX) and Cross Country Healthcare (CCRN)May 18, 2026 | theglobeandmail.comabrdn Healthcare Investors Q1 2026 CommentaryMay 15, 2026 | seekingalpha.comVaxcyte, Inc. (PCVX) Presents at Bank of America Global Healthcare Conference 2026 TranscriptMay 12, 2026 | seekingalpha.comVaxcyte, Inc. $PCVX Shares Sold by State of New Jersey Common Pension Fund DMay 11, 2026 | marketbeat.comNan Fung Trinity HK Ltd. Acquires 38,680 Shares of Vaxcyte, Inc. $PCVXMay 10, 2026 | marketbeat.comVaxcyte Reports First Quarter 2026 Financial Results and Provides Business UpdateMay 6, 2026 | globenewswire.comVaxcyte's Manufacturing-Backed Vaccine Platform Is Redefining The PCV MarketMay 1, 2026 | seekingalpha.com5 Best 52-Week High US Stocks to BuyApril 23, 2026 | insidermonkey.comVaxcyte Inc (PCVX)’s VAX-31 Enters Critical Trial StageApril 23, 2026 | insidermonkey.comIs It Too Late To Consider Vaxcyte (PCVX) After A 95% One-Year Share Price Jump?April 11, 2026 | finance.yahoo.comElvia Cowan Sells 3,000 Shares of Vaxcyte (NASDAQ:PCVX) StockApril 9, 2026 | insidertrades.comVaxcyte to Present at the 25th Annual Needham Virtual Healthcare ConferenceApril 7, 2026 | globenewswire.comVaxcyte joins elite club of stocks with RS ratings over 90March 31, 2026 | msn.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeABCL, PCVX, IMVT, and KYMR Company DescriptionsAbCellera Biologics NASDAQ:ABCL$5.62 -0.75 (-11.77%) Closing price 06/5/2026 04:00 PM EasternExtended Trading$5.78 +0.16 (+2.90%) As of 06/5/2026 07:58 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.AbCellera Biologics Inc. builds an engine for antibody drug discovery and development. Its engine discovers antibodies from natural immune responses, which are pre-enriched for antibodies. The company's preclinical products are ABCL635 for metabolic and endocrine conditions; and ABCL575 for atopic dermatitis. It has a research collaboration and license agreement with Eli Lilly and Company; a research collaboration with Confo Therapeutics for the discovery of therapeutic antibody candidates targeting two undisclosed GPCR targets; and strategic collaboration with Biogen Inc. to discover therapeutic antibodies for neurological conditions, as well as collaboration with Viking Global Investors and ArrowMark Partners. The company was incorporated in 2012 and is headquartered in Vancouver, Canada.Immunovant NASDAQ:IMVT$31.11 -1.56 (-4.78%) Closing price 06/5/2026 04:00 PM EasternExtended Trading$30.58 -0.53 (-1.69%) As of 06/5/2026 07:56 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Immunovant, Inc., a clinical-stage biopharmaceutical company, develops monoclonal antibodies for the treatment of autoimmune diseases. It develops batoclimab, a novel fully human monoclonal antibody that target the neonatal fragment crystallizable receptor for the treatment of myasthenia gravis, thyroid eye disease, chronic inflammatory demyelinating polyneuropathy, and Graves diseases, as well as warm autoimmune hemolytic anemia. The company is headquartered in New York, New York. Immunovant, Inc. operates as a subsidiary of Roivant Sciences Ltd.Kymera Therapeutics NASDAQ:KYMR$74.13 -0.48 (-0.64%) Closing price 06/5/2026 04:00 PM EasternExtended Trading$74.16 +0.03 (+0.03%) As of 06/5/2026 07:12 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Kymera Therapeutics, Inc., a biopharmaceutical company, focuses on discovering and developing novel small molecule therapeutics that selectively degrade disease-causing proteins by harnessing the body's own natural protein degradation system. It engages in developing IRAK4 program, which is in Phase II clinical trial for the treatment of immunology-inflammation diseases, including hidradenitis suppurativa, atopic dermatitis; STAT3 program for the treatment of hematologic malignancies and solid tumors, as well as autoimmune diseases and fibrosis; and MDM2 program to treat hematological malignancies and solid tumors. The company develops STAT6, a Type 2 inflammation in allergic diseases; and TYK2, a treatment for inflammatory bowel disease, psoriasis, psoriatic arthritis, and lupus. The company was incorporated in 2015 and is headquartered in Watertown, Massachusetts.Vaxcyte NASDAQ:PCVX$47.36 -1.40 (-2.87%) Closing price 06/5/2026 04:00 PM EasternExtended Trading$47.35 -0.01 (-0.02%) As of 06/5/2026 05:32 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Vaxcyte, Inc., a clinical-stage biotechnology vaccine company, develops novel protein vaccines to prevent or treat bacterial infectious diseases. Its lead vaccine candidate is VAX-24, a 24-valent investigational pneumococcal conjugate vaccine for the prevention of invasive pneumococcal disease. The company also develops VAX-31 to protect against emerging strains and to help address antibiotic resistance; VAX-A1, a novel conjugate vaccine candidate to prevent disease caused by Group A Streptococcus; VAX-PG, a novel protein vaccine candidate targeting keystone pathogen responsible for periodontitis; and VAX-GI to prevent Shigella, a bacterial illness. The company was formerly known as SutroVax, Inc. and changed its name to Vaxcyte, Inc. in May 2020. Vaxcyte, Inc. was incorporated in 2013 and is headquartered in San Carlos, California. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSilverSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas MarketBeat Week in Review – 06/01 - 06/05 Samsara Just Answered The AI Question—Is Wall Street Ready To Listen? A Lulu of a Miss Sends Lululemon to New Lows—Look Out Below Five Below Down 12% Post Earnings—Is the Selloff Overdone? IREN's 800MW Bet Flips the AI Power Switch Buy the Dip? Broadcom's AI Moat Is Wider Than Ever CrowdStrike Earnings Beat Sparks Selloff—Buy the Dip? The Market Has Ollie’s Bargain Outlet Completely Wrong Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
